logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics chief "really pleased" with human trial data for new skin cream

“It is very difficult to change a healthy barrier and therefore the data showing improvement in some age groups gives us confidence in our partner discussions, and in seeking to develop future applications in disease conditions where the barrier is known to be poor such as eczema,” Dr Cath O’Neill said.

woman touching face
The company says there is further scope to optimise its cream

SkinBioTherapeutics PLC’s (LON:SBTX) chief executive Dr Cath O'Neill said she was “really pleased” with the results from the company’s first human study of its SkinBiotix cream.

The data revealed the product to be well tolerated and efficacious in certain age groups and at certain time points.

“It is very difficult to change a healthy barrier and therefore the data showing improvement in some age groups gives us confidence in our partner discussions, and in seeking to develop future applications in disease conditions where the barrier is known to be poor such as eczema,” O’Neill said.

Hydration

The readout showed that the under 50s group saw a statistically significant increase in skin hydration at day 15, though at day 29 there was no difference in hydration across all the groups monitored.

There was also a small, but statistically significant decrease in transepidermal water loss at day 29 in the over 60s cohort.

“To show efficacy at this stage of development is very exciting since there is a lot of scope for us to further optimise the formulation, potentially altering the dose of the SkinBiotix to make it more suitable for different age groups,” said CEO O’Neill.

Quick facts: SkinBioTherapeutics PLC

Price: 18 GBX

AIM:SBTX
Market: AIM
Market Cap: £23.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read